Metastatic Lung Cancer clinical trials

Explore recruiting metastatic lung cancer clinical trials.

Recruiting metastatic lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IFCT-1904 ENCO-BRAF A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I of TG6050 in the treatment of patients with metastatic lung cancer

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Romania, Croatia, Spain, Greece, Poland, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer

Spain, Romania, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

Spain, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metastatic Lung Cancer trials by city

Metastatic Lung Cancer in Toronto Metastatic Lung Cancer in Vancouver Metastatic Lung Cancer in Montreal Metastatic Lung Cancer in Calgary Metastatic Lung Cancer in Edmonton Metastatic Lung Cancer in Ottawa Metastatic Lung Cancer in Winnipeg Metastatic Lung Cancer in Quebec City Metastatic Lung Cancer in Hamilton Metastatic Lung Cancer in Kitchener Metastatic Lung Cancer in London Metastatic Lung Cancer in Halifax Metastatic Lung Cancer in New York Metastatic Lung Cancer in Los Angeles Metastatic Lung Cancer in Chicago Metastatic Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease